-
Mashup Score: 4Several Barriers Linked to Hindered Access of JAKi Therapy in Patients, Particularly Non-White, With Alopecia Areata - 8 day(s) ago
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0Alopecia Areata Impacts Patient Perception, Quality of Life - 1 month(s) ago
Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Gender Differences, Disease Severity, Income Disparities Drive Financial Burden in AA - 3 month(s) ago
Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Hair Regrowth in Severe Alopecia Areata Improves Quality of Life While Reducing Anxiety, Depression - 4 month(s) ago
People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
Source: www.jaad.orgCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 1Janus kinase inhibitors for alopecia areata - 7 month(s) ago
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection.
Source: www.jaad.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 1
The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 24
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
Source: www.jaad.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0AAD.org Login - 8 month(s) ago
Create a non-member account if you are applying for m embership or need to interact with AAD systems. Non-member accounts do not have access to the member-only sections of our
Source: identity.aad.orgCategories: Dermatology, Latest HeadlinesTweet-
.@TheJEADV study assessed whether exposure to biologics for women with psoriasis is associated with an elevated risk of congenital malformation or miscarriage. Learn more in #DermWorldWeekly - https://t.co/vB2tRsAyui https://t.co/GWd6QzDK6W
-
-
Mashup Score: 0Severe Alopecia Areata Patients Without Regrowth of Scalp Hair Benefit from Dose Increase of Baricitinib - 9 month(s) ago
This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
Patients with #alopeciaareata endure various challenges when attempting to obtain Janus kinase inhibitor therapy, and these challenges may exacerbate racial inequities in care access and quality, according to a new study. https://t.co/01Ie9lol2B